List of Excipients in Branded Drug ZALEPLON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ZALEPLON	zaleplon	21695-376	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	ZALEPLON	zaleplon	21695-376	D&C YELLOW NO. 10
Rebel Distributors Corp	ZALEPLON	zaleplon	21695-376	FD&C BLUE NO. 1
Rebel Distributors Corp	ZALEPLON	zaleplon	21695-376	FD&C GREEN NO. 3

Generic Drugs Containing ZALEPLON

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	zaleplon	0054-0084	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	zaleplon	0054-0084	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	zaleplon	0054-0084	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	zaleplon	0054-0084	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in ZALEPLON?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
2	ANHYDROUS LACTOSE
28	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Zaleplon Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

Zaleplon is a short-acting, Schedule IV sedative-hypnotic with a mature generic market and limited active-ingredient patent protection. The strongest commercial opportunities are differentiated oral dosage forms that improve onset, swallowing, dose flexibility, stability, or administration in patients who cannot use conventional capsules. Excipient innovation can support 505(b)(2) products, line extensions, contract development, and formulation licensing, but it is unlikely to protect a conventional immediate-release capsule by itself.

What is the commercial position of zaleplon?

Zaleplon is a pyrazolopyrimidine hypnotic marketed originally as Sonata by King Pharmaceuticals and later available from multiple generic manufacturers. The FDA approved Sonata capsules in 1999 under NDA 20-859 for short-term treatment of insomnia characterized by difficulty falling asleep. The recommended adult dose is 10 mg at bedtime, with a 5 mg dose for some patients and a maximum recommended dose of 20 mg.[1]

Attribute	Zaleplon
Active ingredient	Zaleplon
Drug class	Nonbenzodiazepine sedative-hypnotic
Original brand	Sonata
FDA dosage forms	Immediate-release capsules
Common strengths	5 mg and 10 mg
Controlled-substance status	Schedule IV in the United States
Approximate elimination half-life	One hour
Main therapeutic use	Short-term insomnia treatment
Primary competitive threat	Low-cost generic capsules
Biosimilar relevance	None; zaleplon is a small molecule
Commercial maturity	Mature, genericized market

Zaleplon’s pharmacokinetic profile creates a clear formulation target. It is rapidly absorbed, reaches peak plasma concentration in approximately one hour, and has a short elimination half-life. Food, particularly a high-fat meal, can delay absorption and reduce the speed of onset.[1] A formulation that preserves rapid release while reducing food effects has a stronger commercial rationale than a conventional capsule with a different excipient grade.

What excipients are used in zaleplon capsules?

The original Sonata capsule uses standard pharmaceutical excipients, including lactose, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The capsule shell contains gelatin and colorants. Exact excipient composition varies by strength and manufacturer.[1]

Generic zaleplon capsules may use different fillers, binders, disintegrants, lubricants, glidants, colorants, and capsule-shell systems. FDA approval does not require an ANDA formulation to use the same inactive ingredients as the reference listed drug, provided the differences meet applicable safety, quality, and performance requirements.[2]

Functional role of common excipients

Excipient category	Typical function in zaleplon capsules	Development relevance
Lactose or microcrystalline cellulose	Diluent and capsule fill carrier	Affects powder flow, content uniformity, and fill weight
Pregelatinized starch	Binder and disintegrant	Supports capsule rupture and powder compactibility
Sodium lauryl sulfate	Wetting agent	May improve dissolution of poorly wettable drug particles
Colloidal silicon dioxide	Glidant	Improves flow and reduces fill variability
Magnesium stearate	Lubricant	Excess levels can slow wetting and dissolution
Crospovidone or croscarmellose sodium	Superdisintegrant	Candidate for faster capsule-fill dispersion
Mannitol or xylitol	Water-soluble diluent	Useful in orally disintegrating and taste-masked products
Hypromellose or ethylcellulose	Film-forming or release-controlling polymer	Supports multiparticulate and modified-release platforms
Cyclodextrins	Solubilizer and taste-masking aid	May improve dissolution but can increase dose-formulation bulk
Ion-exchange resins	Taste masking	Relevant for orally disintegrating tablets and pediatric products
Lipids or surfactants	Solubilization and wetting	Useful for low-dose, fast-onset formulations

The low dose of zaleplon is favorable for taste masking and orally disintegrating formats. The drug substance’s intense pharmacologic activity also means that content uniformity, blend segregation, and dose carryover require tight process controls.

What excipient strategies can differentiate zaleplon products?

Fast-disintegrating oral dosage forms

The most direct opportunity is a tablet or capsule-fill system that disperses rapidly in the oral cavity or stomach. Candidate platforms include:

• Mannitol-based orally disintegrating tablets.
• Crospovidone or croscarmellose sodium for rapid water uptake.
• Spray-dried composite particles.
• Co-processed excipients that improve powder flow and tablet tensile strength.
• Effervescent systems, subject to moisture and stability controls.
• Thin films or rapidly dissolving oral strips.

A fast-disintegrating product may improve administration for patients who have difficulty swallowing capsules. It does not automatically establish clinical superiority. The product would need to demonstrate acceptable dissolution, stability, dose uniformity, and a pharmacokinetic profile consistent with the proposed regulatory pathway.

Taste masking

Zaleplon’s bitter taste is a central barrier to an orally disintegrating or oral-film product. Excipients and technologies that can be evaluated include:

• Polymer coating of drug particles.
• Ion-exchange resin complexes.
• Cyclodextrin inclusion complexes.
• Lipid or wax barriers.
• pH-dependent polymers.
• Sweetener and flavor systems.
• Microencapsulation with controlled rupture after swallowing.

Taste masking must balance palatability with rapid drug release. A coating that reduces bitterness but delays dissolution could undermine zaleplon’s principal clinical value, which is rapid sleep initiation.

Food-effect reduction

The reference product label warns that a high-fat meal can delay absorption. A formulation designed for consistent exposure after food could provide a stronger product profile than a simple fast-disintegrating tablet.[1]

Potential approaches include:

• Amorphous solid dispersions.
• Surfactant-assisted wetting.
• Nanocrystalline zaleplon.
• Lipid-based self-emulsifying systems.
• Porous particles with increased surface area.
• Spray-dried drug-excipient matrices.

These systems require careful control of supersaturation, precipitation, and dose uniformity. A formulation that accelerates release under fasted conditions but produces excessive exposure after food may create a regulatory and safety problem.

Liquid and pediatric formulations

An oral solution, suspension, or reconstitutable powder could address patients who cannot swallow capsules. The commercial opportunity is narrower because zaleplon is indicated for insomnia and is a Schedule IV controlled substance. Pediatric development would require a specific clinical and regulatory rationale, not simply a reformulation.

Important excipient issues include:

• Preservative selection.
• Alcohol and propylene glycol exposure.
• Sedimentation and redispersibility.
• Container-closure compatibility.
• Dosing-device accuracy.
• Child-resistant packaging.
• Palatability and accidental-ingestion risk.

A liquid product may be more defensible under a 505(b)(2) strategy if it solves a clinically recognized administration problem and requires new safety or pharmacokinetic data.

What patents protect zaleplon and its formulations?

The original zaleplon compound patent family includes U.S. Patent No. 4,626,538, covering pyrazolopyrimidine derivatives associated with the compound class. The original active-ingredient patent protection is no longer a practical barrier to ordinary generic entry. Sonata’s original U.S. regulatory exclusivity also expired many years ago.[1][3]

Current patent value is therefore more likely to arise from a specific formulation, delivery system, manufacturing process, or method of use than from zaleplon itself.

IP category	Protection level for a new product	Commercial implication
Zaleplon molecule	Low	Generic competition is established
Conventional capsule	Very low	Difficult to distinguish from ANDA products
Taste-masked ODT	Moderate, if technically narrow	Potential 505(b)(2) or licensing asset
Oral film	Moderate	Manufacturing and dose-uniformity claims may matter
Food-effect-reducing formulation	Moderate to high if clinically demonstrated	Potential differentiated product
Liquid formulation	Moderate	Utility depends on target population
Manufacturing process	Moderate	Can protect cost, purity, or particle engineering
New indication	Variable	Requires clinical evidence and method-of-use claims
Modified release	Moderate but clinically complex	May conflict with short half-life objective

A patent strategy should claim more than a generic ingredient list. High-value claims would focus on particle-size distribution, crystalline form, coated-particle architecture, dissolution profile, pharmacokinetic parameters, food-effect reduction, manufacturing conditions, and clinically meaningful administration benefits.

When does zaleplon lose exclusivity?

Zaleplon has already lost the exclusivity that protected the original Sonata product. FDA-approved generic zaleplon capsules have been available for years, and the market no longer depends on an active-ingredient patent barrier.

Paragraph IV challenges

A Paragraph IV challenge is most relevant to an ANDA applicant asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For a mature product such as zaleplon, the commercial issue is not whether the original product can be challenged. It is whether a later, differentiated product contains a still-enforceable formulation or method-of-use patent.

Potential Paragraph IV exposure for a new zaleplon product could arise from:

• A formulation patent listed in the Orange Book.
• A polymorph or particle-engineering patent.
• A delivery-system patent.
• A method-of-use patent covering a specific insomnia population.
• A patent covering a food-effect or pharmacokinetic profile.

A generic capsule developer generally faces low litigation risk if no relevant active patent is listed or enforceable. A developer of a branded ODT, film, or liquid product would face greater freedom-to-operate risk because delivery-system patents may overlap even when the active ingredient is unprotected.

What is the Orange Book status of zaleplon?

The FDA Orange Book remains the controlling source for current listed patents, exclusivity, therapeutic-equivalence codes, and reference listed drug information.[3] Zaleplon’s key commercial status is that it is an established small-molecule product with generic capsule competition rather than a product protected by current NCE exclusivity.

The practical Orange Book implications are:

1. Conventional zaleplon capsules can be pursued through the ANDA pathway if the applicant meets sameness, bioequivalence, quality, and labeling requirements.
2. A novel dosage form may require a 505(b)(2) application if it relies on FDA findings for the reference drug but differs in formulation, route, dosage form, or clinical use.
3. Orange Book patent listings should be reviewed before launch of any differentiated product.
4. A formulation patent is commercially useful only if it is valid, enforceable, listed when eligible, and difficult to design around.

Which companies are challenging zaleplon, and what is the generic landscape?

Zaleplon is supplied by multiple generic manufacturers and labelers. The market is characterized by price competition, multiple approved capsule products, and limited differentiation. Generic availability reduces the value of a standard capsule license and increases the importance of manufacturing cost.

The most credible commercial entrants are:

• Established generic manufacturers with controlled-substance infrastructure.
• Contract manufacturers with low-dose powder-handling capabilities.
• Specialty companies developing orally disintegrating or liquid controlled substances.
• Drug-delivery companies with taste-masking and particle-engineering platforms.
• Firms pursuing 505(b)(2) products for swallowing difficulty, rapid onset, or reduced food effect.

There is no biosimilar pathway for zaleplon. Biosimilar risk is therefore irrelevant; the relevant threat is abbreviated new drug applications and branded reformulations.

What generic launch risks exist for a new zaleplon formulation?

A new product would face five principal launch risks.

Price compression

A conventional 5 mg or 10 mg capsule has limited pricing power because generic alternatives are available. An excipient change alone is unlikely to justify a premium.

Regulatory classification

The product may be eligible for an ANDA if it is pharmaceutically equivalent and bioequivalent to the reference product. A new dosage form, delivery technology, or clinical claim may require a 505(b)(2) application. That route can require additional pharmacokinetic, food-effect, safety, or clinical studies.[4]

Controlled-substance controls

Zaleplon is Schedule IV. Manufacturing, distribution, inventory control, recordkeeping, quotas where applicable, and diversion controls increase operational complexity.[5]

Clinical differentiation

A faster in-vitro disintegration time does not by itself demonstrate faster sleep onset. Commercial claims should be tied to pharmacokinetic or clinical endpoints that regulators accept.

Formulation freedom to operate

Excipients are generally difficult to protect broadly because many are established materials. Patent value must come from the combination, structure, process, or demonstrated performance.

How strong is the patent estate for zaleplon?

The patent estate is weak for the active ingredient and conventional capsule but can be moderate for a technically differentiated delivery system.

Stronger claim areas

• Specific taste-masked particles.
• Defined particle-size or surface-area parameters.
• Robust food-effect reduction.
• Controlled disintegration with rapid absorption.
• Novel oral-film manufacturing.
• Stable liquid or suspension formulations.
• Low-moisture processes that preserve potency and content uniformity.
• Device-packaging combinations that support accurate controlled-substance dosing.

Weaker claim areas

• Use of standard lactose or microcrystalline cellulose.
• A capsule containing zaleplon and routine excipients.
• Broad claims to rapid dissolution without a defined structure.
• Claims that merely substitute one common disintegrant for another.
• Method claims covering ordinary insomnia treatment without a novel patient population or regimen.

The strongest commercial asset would combine patent claims with difficult-to-reproduce manufacturing know-how. Particle engineering, coating uniformity, blend control, and moisture management may create meaningful barriers even when the patent claims are narrow.

What licensing deals and partnership opportunities exist?

The most realistic licensing opportunities are platform-based rather than molecule-based. A zaleplon owner could license:

• Taste-masking technology for an ODT.
• Oral-film manufacturing technology.
• Nanocrystal or amorphous-dispersion technology.
• A controlled-substance liquid formulation.
• A contract manufacturing process for low-dose, high-potency blends.
• A regional commercial right for a 505(b)(2) product.

A conventional generic capsule is more suitable for contract manufacturing or supply agreements than for a high-value exclusive license. A differentiated formulation with patent protection, clinical data, and a clear target population could support an exclusive regional license or co-development transaction.

Publicly visible commercial value is more likely to be measured through product margin and licensing economics than through current Sonata revenue, because the original branded product has been displaced by generics. Standalone current zaleplon revenue is not consistently reported by major manufacturers, and company filings generally aggregate products or therapeutic categories rather than disclose zaleplon sales separately.

How does zaleplon compare with other insomnia drugs?

Product	Differentiation opportunity	Generic pressure	Formulation rationale
Zaleplon	Very rapid onset and short duration	High	ODT, film, food-effect reduction
Zolpidem	Broad immediate-release and extended-release use	High	Abuse deterrence, modified release, sublingual products
Eszopiclone	Longer duration	High	Taste masking and next-day exposure management
Ramelteon	Melatonin-receptor mechanism	Moderate to high	Solubility and adherence products
Suvorexant and lemborexant	Orexin antagonism	Lower or evolving	Modified release and dose optimization
Low-dose doxepin	Different pharmacology and generic supply	High	Liquid and low-dose precision

Zaleplon’s short half-life is both its primary advantage and its commercial constraint. Modified release is less intuitive than for longer-acting hypnotics. The more coherent strategy is rapid, predictable delivery with minimal residual exposure.

What is the best commercial excipient strategy?

The preferred strategy is a two-track program.

Track one: low-cost generic optimization

Develop a capsule formulation that improves:

• Blend uniformity at 5 mg.
• Dissolution consistency.
• Moisture stability.
• Manufacturing yield.
• Capsule-fill speed.
• Supply-chain resilience.

This strategy supports ANDA competition but usually produces limited pricing power.

Track two: differentiated 505(b)(2) product

Develop a taste-masked ODT, oral film, or low-volume liquid formulation with evidence for:

• Rapid disintegration.
• Acceptable taste.
• Reduced food-related delay.
• Consistent exposure.
• Improved administration for patients with swallowing difficulty.
• Commercially meaningful adherence or onset benefits.

This track requires more development capital but offers stronger licensing and margin potential.

Key Takeaways

• Zaleplon’s active ingredient and conventional capsule market are mature and heavily genericized.
• The strongest excipient opportunities involve taste masking, rapid disintegration, food-effect reduction, oral films, and liquid delivery.
• A standard excipient substitution is unlikely to support a durable premium or strong patent position.
• The most credible differentiated route is a 505(b)(2) product with pharmacokinetic or administration evidence.
• Zaleplon is a small molecule, so biosimilar risk does not apply.
• Schedule IV controls increase manufacturing, distribution, and diversion-management requirements.
• Patent strength is low for the molecule and moderate for a technically specific delivery system.
• Commercial value will depend on clinical differentiation, manufacturing difficulty, and reimbursement strategy rather than on the original Sonata franchise.

FAQs

Can zaleplon be developed as an orally disintegrating tablet?

Yes. Its low dose makes an ODT technically feasible. Taste masking, dose uniformity, moisture protection, and rapid dissolution are the principal development challenges.

Is a zaleplon oral film commercially attractive?

It can be attractive for patients with swallowing difficulty, but the film must deliver a precise low dose and avoid delayed absorption. Film thickness, content uniformity, packaging, and controlled-substance handling require validation.

Would a new zaleplon excipient combination require an ANDA or 505(b)(2) application?

An equivalent capsule may qualify for an ANDA. A new dosage form, delivery system, route, or clinically differentiated formulation may require a 505(b)(2) application.

Can excipients reduce zaleplon’s food effect?

They may reduce variability through improved wetting, dissolution, particle engineering, or lipid-based delivery. The claim must be demonstrated through comparative pharmacokinetic studies under fed and fasted conditions.

Is zaleplon suitable for a pediatric liquid product?

Technically, a liquid is feasible. Commercial and regulatory viability depends on a defined clinical need, safety evidence, palatability, dosing accuracy, preservative system, packaging, and Schedule IV controls.

References

1. U.S. Food and Drug Administration. (1999). Sonata (zaleplon) capsules prescribing information, NDA 20-859. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2): Guidance for industry. FDA.

5. U.S. Drug Enforcement Administration. (2024). Controlled substances act, Schedule IV. U.S. Department of Justice.

6. United States Patent and Trademark Office. (1986). U.S. Patent No. 4,626,538, pyrazolopyrimidine derivatives. USPTO.